Our Medicines
Delivering Treatments
for Patients
Building on a more than 125-year-old heritage and a culture of innovation and inclusion, we’re forging better futures through medicine for people everywhere.
We’re leveraging our cutting-edge science and technology and currently have innovative oncology medicines approved in the U.S. Our other U.S. medicines include those to treat thrombosis, and iron deficiency anemia, as well as reduce stroke risk.
U.S. Medicines
intended for use in the U.S.
(datopotamab deruxtecan-dlnk)
Get more information
See full prescribing Information and medication guide.
(fam-trastuzumab deruxtecan-nxki)
Get more information
See full prescribing Information, including boxed warnings and medication guide.
(ferric carboxymaltose injection)
Get more information
(edoxaban) tablets
Get more information
See full prescribing Information, including boxed warnings and medication guide.
See full prescribing Information, including boxed warning regarding liver toxicity and medication guide.
See full prescribing Information, including boxed warning and medication guide.
Have a question about a medicine?
Please call the Daiichi Sankyo Contact Center at 1-877-4DS-PROD (1-877-437-7763) if you have a question about any of our medicines or to report any adverse reactions to our medicines.
To report negative side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch